Ex-vivo thrombolytic gene therapy for vein graft patency: The frontier for development of selective, localised therapeutic approaches

Christoph E. Hagemeyer; Karlheinz Peter

doi:10.1160/TH09-06-0343

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2009; 102(01): 03-04
DOI: 10.1160/TH09-06-0343

Editorial Focus

Schattauer GmbH

Ex-vivo thrombolytic gene therapy for vein graft patency: The frontier for development of selective, localised therapeutic approaches

Christoph E. Hagemeyer

¹Atherothrombosis and Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia

,

Karlheinz Peter

¹Atherothrombosis and Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia

› Author Affiliations

Abstract

Full Text

References

References
1 Fuchs H, Bachran C. Targeted tumor therapies at a glance. Curr Drug Targets 2009; 10: 89-93.
2 Thomas A, Wyatt M, Newby A. Reduction of early vein graft thrombosis by tissue plasminogen activator gene transfer. Thromb Haemost 2009; 102: 145152.
3 Ding BS, Hong N, Murciano JC. et al. Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature. Blood 2008; 111: 1999-2006.
4 Hata M, Sezai A, Niino T. et al. What is the optimal management for preventing saphenous vein graft diseases?: early results of intravascular angio scopic assessment. Circ J 2007; 71: 286-287.
5 Jeremy JY, Mehta D, Bryan AJ. et al. Platelets and saphenous vein graft failure following coronary artery bypass surgery. Platelets 1997; 08: 295-309.
6 Lu HR, Gold HK, Wu Z. et al. G4120, an Arg-Gly-Asp containing pentapeptide, enhances arterial eversion graft recanalization with recombinant tissue type plasminogen activator in dogs. Thromb Haemost 1992; 67: 686-691.
7 Collen D, Stassen JM, Yasuda T. et al. Comparative thrombolytic properties of tissue type plas minogen activator and of a plasminogen activator inhibitor1 resistant glycosylation variant, in a com bined arterial and venous thrombosis model in the dog. Thromb Haemost 1994; 72: 98-104.
8 van der Meer J, Hillege HL, Dunselman PH. et al. Oral anticoagulation in the prevention of one year vein graft occlusion after aortocoronary bypass surgery: optimal therapeutic range and practical limitations. CABADAS Research Group of the Interuniversity Cardiology Institute of The Netherlands. Thromb Haemost 1994; 72: 676-681.
9 Belch JJ, Lowe GD, Pollock JG. et al. Low dose heparin in the prevention of deep- vein thrombosis after aortic bifurcation graft surgery. Thromb Haemost 1980; 42: 1429-1433.
10 Collen D, Lu HR, Stassen JM. et al. Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet mediated thrombosis. Thromb Haemost 1994; 71: 95-102.
11 More RS, Underwood MJ, De Bono DP. Targeting fibrinolytic agents to the vessel wall: a new therapeutic niche?. Thromb Haemost 1994; 71: 158-159.
12 Hagemeyer CE, Tomic I, Jaminet P. et al. Fibrintar geted direct factor Xa inhibition: construction and characterization of a recombinant factor Xa inhibitor composed of an anti-fibrin single-chain antibody and tick anticoagulant peptide. Thromb Haemost 2004; 92: 47-53.
13 Stoll P, Bassler N, Hagemeyer CE. et al. Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation with-out bleeding time prolongation. Arterioscler Thromb Vasc Biol 2007; 27: 1206-1212.
14 Danielyan K, Ding BS, Gottstein C. et al. Delivery of anti-platelet endothelial cell adhesion molecule single-chain variable fragment-urokinase fusion protein to the cerebral vasculature lyses arterial clots and attenuates postischemic brain edema. J Pharmacol Exp Ther 2007; 321: 947-952.
15 Ding BS, Gottstein C, Grunow A. et al. Endothelial targeting of a recombinant construct fusing a PECAM1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature. Blood 2005; 106: 4191-4198.
16 Hagemeyer CE, Tomic I, Weirich U. et al. Construction and characterization of a recombinant plas minogen activator composed of an anti-fibrin single-chain antibody and low-molecular-weight urokinase. J Thromb Haemost 2004; 02: 797-803.
17 West NE, Qian H, Guzik TJ. et al. Nitric oxide syn thase (nNOS) gene transfer modifies venous bypass graft remodeling: effects on vascular smooth muscle cell differentiation and superoxide production. Circulation 2001; 104: 1526-1532.
18 Chen SJ, Wilson JM, Muller DW. Adenovirusme diated gene transfer of soluble vascular cell adhesion molecule to porcine interposition vein grafts. Circulation 1994; 89: 1922-1928.
19 Hagemeyer CE, Ahrens I, Bassler N. et al. Genetic transfer of fusion proteins effectively inhibits VCAM-1-mediated cell adhesion and transmigration via inhibition of cytoskeletal anchorage. J Cell Mol Med. 2009 in press.
20 Tabuchi N, Shichiri M, Shibamiya A. et al. Non-viral in vivo thrombomodulin gene transfer prevents early loss of thromboresistance of grafted veins. Eur J Cardiothorac Surg 2004; 26: 995-1001.
21 George SJ, Lloyd CT, Angelini GD. et al. Inhibition of late vein graft neointima formation in human and porcine models by adeno-virus-mediated over expression of tissue inhibitor of metalloproteinase3. Circulation 2000; 101: 296-304.
22 Dichek DA, Anderson J, Kelly AB. et al. Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors. Circulation 1996; 93: 301-309.
23 Langer HF, Gawaz M. Platelet-vessel wall interactions in atherosclerotic disease. Thromb Haemost 2008; 99: 480-486.